Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) EBIT Margin (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed EBIT Margin for 16 consecutive years, with 268.51% as the latest value for Q4 2025.

  • For Q4 2025, EBIT Margin rose 13134.0% year-over-year to 268.51%; the TTM value through Dec 2025 reached 306.53%, down 12332.0%, while the annual FY2025 figure was 306.53%, 12665.0% down from the prior year.
  • EBIT Margin hit 268.51% in Q4 2025 for Sangamo Therapeutics, up from 6119.28% in the prior quarter.
  • Across five years, EBIT Margin topped out at 21.52% in Q3 2024 and bottomed at 10712.27% in Q1 2024.
  • Average EBIT Margin over 5 years is 1877.28%, with a median of 207.46% recorded in 2022.
  • Year-over-year, EBIT Margin crashed -1072368bps in 2024 and then soared 1031932bps in 2025.
  • Sangamo Therapeutics' EBIT Margin stood at 169.58% in 2021, then decreased by -20bps to 203.42% in 2022, then tumbled by -1394bps to 3039.13% in 2023, then soared by 87bps to 399.85% in 2024, then soared by 33bps to 268.51% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 268.51%, 6119.28%, and 97.54% for Q4 2025, Q3 2025, and Q2 2025 respectively.